Core Protein Resources Center, Daegu Gyeongbuk Institute of Science and Technology, Daegu, South Korea.
Adv Exp Med Biol. 2021;1187:305-322. doi: 10.1007/978-981-32-9620-6_15.
Biomarkers factor into the diagnosis and treatment of almost every patient with cancer. The innovation in proteomics follows improvement of mass spectrometry techniques and data processing strategy. Recently, proteomics and typical biological studies have been the answer for clinical applications. The clinical proteomics techniques are now actively adapted to protein identification in large patient cohort, biomarker development for more sensitive and specific screening based on quantitative data. And, it is important for clinical, translational researchers to be acutely aware of the issues surrounding appropriate biomarker development, in order to facilitate entry of clinically useful biomarkers into the clinic. Here, we discuss in detail include the case research for clinical proteomics. Furthermore, we give an overview on the current developments and novel findings in proteomics-based cancer biomarker research.
生物标志物几乎参与了每个癌症患者的诊断和治疗。蛋白质组学的创新是伴随着质谱技术和数据处理策略的改进而出现的。最近，蛋白质组学和典型的生物学研究已经成为临床应用的答案。临床蛋白质组学技术现在正在积极地适应于在大型患者群体中进行蛋白质鉴定、基于定量数据的更敏感和更特异的筛查生物标志物的开发。对于临床和转化研究人员来说，敏锐地意识到围绕适当的生物标志物开发的问题非常重要，以便将临床上有用的生物标志物引入临床。在这里，我们详细讨论了包括临床蛋白质组学案例研究在内的问题。此外，我们还概述了基于蛋白质组学的癌症生物标志物研究的最新进展和新发现。
